Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$887.11 USD

887.11
832,981

-3.96 (-0.44%)

Updated Oct 3, 2024 12:21 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Cardinal Health (CAH) Beats Q3 Earnings and Revenue Estimates

Cardinal Health's (CAH) fiscal third-quarter results benefit from strong segmental performance.

LHC Group (LHCG) Earnings and Revenues Beat Estimates in Q1

LHC Group (LHCG) continues to gain from home health services and hospice admissions, which improved year over year in Q1.

Radius' (RDUS) Q1 Earnings Miss Estimates, Sales Surpass

Radius (RDUS) reports wider-than-expected loss but beats sales estimates in the first quarter. The company lowers guidance for 2020.

Kinjel Shah headshot

Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY

Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.

OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates

OPKO Health's (OPK) first-quarter results benefit from increase in RAYALDEE prescriptions.

Globus Medical (GMED) Misses on Q1 Earnings and Revenues

Globus Medical (GMED) witnesses around $20 million of COVID-19 related adverse impact on its Q1 sales.

Omnicell (OMCL) Q1 Earnings Top, Operating Margin Rises

Omnicell's (OMCL) Q1 revenues suffer due to slowdown in hospital purchasing decisions and product bookings.

Avanos Medical (AVNS) Q1 Earnings Lag Estimates, Revenues Top

Avanos Medical's (AVNS) first-quarter results benefit from segmental contribution.

DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results

DENTSPLY SIRONA's (XRAY) first-quarter 2020 preliminary results reflect weak segmental performance and decline in revenues.

Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook

Integra's (IART) first-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.

Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates

Glaukos (GKOS) witnessed a contraction in gross margin but year-over-year revenue surge in Q1.

Bruker (BRKR) Q1 Earnings Miss Estimates, Guidance Suspended

Bruker's (BRKR) first-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.

Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates

Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.

Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates

Novo Nordisk (NVO) beats on Q1 sales and earnings, and maintains outlook amid the coronavirus pandemic.

Amedisys (AMED) Q1 Earnings Beat, Operating Margin Falls

Amedisys (AMED) notes that COVID-19 started impacting its volumes and costs beginning the second half of March.

NuVasive's (NUVA) Q1 Earnings Beat Estimates, Revenues Miss

NuVasive's (NUVA) operating segments experience slowdown in first-quarter volumes due to the coronavirus pandemic.

QIAGEN (QGEN) Q1 Earnings Lag Estimates, Operating Margin Up

QIAGEN (QGEN) registered robust revenue growth across all geographies and each of its operating segments in Q1 despite the coronavirus-led economic crisis.

AmerisourceBergen (ABC) Q2 Earnings & Revenues Top Estimates

AmerisourceBergen's (ABC) fiscal second-quarter earnings benefit from segmental growth.

Bio-Rad (BIO) Beats Q1 Earnings Estimates, Withdraws View

Bio-Rad's (BIO) first-quarter 2020 results reflect strong segmental performance boosted by coronavirus-led increased testing demand.

Exact Sciences' (EXAS) Q1 Earnings Fall Y/Y, Margin Expands

Exact Sciences' (EXAS) first-quarter 2020 results reflect strong performance by Screening segment amid the coronavirus-led economic crisis.

Nevro (NVRO) Earnings and Revenues Beat Estimates in Q1

Nevro's (NVRO) domestic revenues improved on a year-over-year basis in Q1.

Becton Dickinson (BDX) Q2 Earnings and Revenues Top Estimates

Becton Dickinson's (BDX) second-quarter results reflect solid performance by the core Life Sciences and Interventional segments.

Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View

Myriad Genetics (MYGN) reports revenue declines in both reporting segments in Q3 resulting from coronavirus-led business disruptions.

CVS Health (CVS) Q1 Earnings Top Estimates, Costs Escalate

Within CVS Health's (CVS) Retail/LTC, the coronavirus pandemic results in greater use of 90-day prescriptions and early refills of maintenance medications in the quarter.

Jazz Pharma (JAZZ) Misses on Q1 Earnings & Sales, Cuts View

Jazz Pharmaceuticals (JAZZ) reports lower-than-expected first-quarter 2020 earnings and revenues. It lowers its guidance for 2020. Shares drop.